Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

BUY

Longer term chart doesn't paint the greatest picture. The short term chart is showing a bullish pattern in that there is a falling wedge. There could be a breakout, but you have to watch that it doesn't make a 52 week low on you. The sector also looks favourable.

WEAK BUY

Looks cheap. Starting to generate cash. So many issues with this company regarding governance, management and accounting. Welbutrin has been a big money spinner for them, but it will be coming off patent, so competition will increase. This is already in the stock. Could trade higher. High risk and volatile.

DON'T BUY

Share price has underperformed pretty dramatically. Industry has been under pressure and they have had some internal issues.

DON'T BUY

Has been having a difficult time. A lot of questions on their ability to grow and make money. In a difficult space.

DON'T BUY

Even though it looks cheap on a valuation basis, there still seems to be risk of events that can't be forcast.

TOP PICK

Use a stop loss just below the $17 area. As cheap as it's been in a long time. Good balance sheet and good FMV up in the $50's.

WEAK BUY

Dropped a little on the rumour that a competitor was going to have a generic for their drug Wellbutrin. Have to see how that plays out. Not a bad value. Medium risk.

DON'T BUY

Had invested because it appeared to be a good cash flow generator, but accounting numbers were suspect, so sold. Not everything is corrected yet.

DON'T BUY

This market doesn't tolerate miscues or confusion. Move on.

DON'T BUY

Has been struggling for some time which is an indication that there are issues.

DON'T BUY

If it breaks below $20, it could possibly be a short.

DON'T BUY

Had a pretty good quarter. A lot of negatives to overcome.

DON'T BUY

Got a letter from the FDA saying their drug Remedal (?) saying it was approvable (not approved). Thinks they will have to run another trial which will be expensive and delay the appproval. Thinks we will get a nasty surprise.

DON'T BUY

A controversial stock, so has come down a great deal. Now seems to be in a narrow trading range. AT a P/E of 14 X, it looks quite cheap. Made some good changes in management. The stock needs more seasoning time in order to restore investors' confidence.

BUY

Became interested in this company when Jim Pattison took an interest.

Showing 391 to 405 of 714 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)